The Efficacy and Safety of Nab-Paclitaxel Plus Anlotinib in Small-Cell Lung Cancer for Second-Line Therapy.

Li-Jun Tian, Fei-Fei Zhou, Min Dai, Jun-Li Liu, Qi-Sen Guo

Abstract read

In one paragraph

Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Li-Jun TianDepartment of Oncology, Shandong University Cancer Center, Jinan, Shandong, China.ORCID https://orcid.org/0009-0009-1517-1906

Fei-Fei ZhouDepartment of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, China.

Min DaiDepartment of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, China.

Jun-Li LiuDepartment of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, China.

Qi-Sen GuoDepartment of Oncology, Shandong University Cancer Center, Jinan, Shandong, China.ORCID https://orcid.org/0009-0002-9957-4321

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExtensive Small-cell lung cancer (ES-SCLC) has a poor prognosis following the failure of first-line therapy based immune checkpoint inhibitors. This study aimed to evaluate the efficacy and safety of nab-paclitaxel combined with anlotinib as second-line treatment for relapsed SCLC.

methodsPatients were divided into two groups: patients receiving 125 mg/m

resultsBetween January 1, 2023, and July 31, 2024, 48 patients were enrolled into the study. The median PFS was 6.0 months in the ANNAB group and 4.7 months in the NAP group (p = 0.0004). ORR was significantly higher in the ANNAB group than in the NAP group (37.5% vs. 8.3%, p = 0.0363). The median OS was 10.0 months in the ANNAB group compared to 7.3 months in the NAP group (p < 0.0001). There were no significant differences in adverse events between the two groups.

conclusionsThe combination of nab-paclitaxel and anlotinib as second-line treatment for recurrent SCLC demonstrated promising efficacy and an acceptable toxicity profile, suggesting its potential as a viable therapeutic strategy.

Indexed as

AlbuminsAntineoplastic Combined Chemotherapy ProtocolsIndolesLung NeoplasmsPaclitaxelQuinolinesSmall Cell Lung CarcinomaAdultAgedFemaleHumansMaleMiddle Aged130-nm albumin-bound paclitaxelAlbuminsanlotinibIndolesPaclitaxelQuinolines

Identifiers

PMID42109188

DOI10.1111/1759-7714.70290

PMCPMC13158806

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.